A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 4874 participants.
Also called NCT05636176
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 4,874 participants
- Sponsor
- Registry
-
NCT05636176 -
jRCT2031230085
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Argentina, Australia, Austria, Belgium, Bosnia & Herzegovina, Brazil, Bulgaria, Canada, China, Colombia, Croatia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Japan, Latvia, Lithuania, Malaysia, Mexico, Netherlands, North Macedonia, Norway, Poland, Portugal, Romania, Serbia, Singapore, Slovakia, Slovenia, South Africa, South Korea, Spain, Taiwan, Thailand, Türkiye, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT05636176. Randomized; quadruple masking; primary purpose treatment. Start 2023-05-08 (actual); primary completion 2026-09-03 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
- Acronym
- HERMES
- Condition
- Heart Failure
- Intervention (Drug)
- Ziltivekimab
- Intervention (Drug)
- Placebo
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct05636176- Content hash
46751ed7c2c639d2092af1df3af577e0999cf86edcf46c2fdbc41e8f3ae1fd9a